Arcellx initiated with an Overweight at Morgan Stanley

Morgan Stanley initiated coverage of Arcellx with an Overweight rating and $81 price target. Phase 1 data in multiple myeloma supports both a potential best-in-class CAR-T profile in this late-line indication and evidence of a broader platform around the D-Domain proprietary synthetic binding domain, the analyst tells investors in a research note.